Oncopeptides AB
Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is Pepaxti (melflufen), a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. The company's PDC platform desig… Read more
Oncopeptides AB (ONCO) - Total Assets
Latest total assets as of September 2025: Skr211.28 Million SEK
Based on the latest financial reports, Oncopeptides AB (ONCO) holds total assets worth Skr211.28 Million SEK as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Oncopeptides AB - Total Assets Trend (2014–2024)
This chart illustrates how Oncopeptides AB’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Oncopeptides AB - Asset Composition Analysis
Current Asset Composition (December 2024)
Oncopeptides AB's total assets of Skr211.28 Million consist of 88.9% current assets and 11.1% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 73.1% |
| Accounts Receivable | Skr11.14 Million | 4.6% |
| Inventory | Skr4.37 Million | 1.8% |
| Property, Plant & Equipment | Skr27.11 Million | 11.1% |
| Intangible Assets | Skr0.00 | 0.0% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2014–2024)
This chart illustrates how Oncopeptides AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Oncopeptides AB's current assets represent 88.9% of total assets in 2024, a decrease from 98.6% in 2014.
- Cash Position: Cash and equivalents constituted 73.1% of total assets in 2024, down from 91.2% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2014.
- Asset Diversification: The largest asset category is property, plant & equipment at 11.1% of total assets.
Oncopeptides AB Competitors by Total Assets
Key competitors of Oncopeptides AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Oncopeptides AB - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Oncopeptides AB generates 0.13x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Oncopeptides AB is currently not profitable relative to its asset base.
Oncopeptides AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.42 | 6.25 | 2.52 |
| Quick Ratio | 3.27 | 6.16 | 2.50 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr135.39 Million | Skr 243.07 Million | Skr 540.40 Million |
Oncopeptides AB - Advanced Valuation Insights
This section examines the relationship between Oncopeptides AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 117.85 |
| Latest Market Cap to Assets Ratio | 0.14 |
| Asset Growth Rate (YoY) | 2.4% |
| Total Assets | Skr244.19 Million |
| Market Capitalization | $34.55 Million USD |
Valuation Analysis
Below Book Valuation: The market values Oncopeptides AB's assets below their book value (0.14 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Oncopeptides AB's assets grew by 2.4% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Oncopeptides AB (2014–2024)
The table below shows the annual total assets of Oncopeptides AB from 2014 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Skr244.19 Million | +2.44% |
| 2023-12-31 | Skr238.38 Million | -38.14% |
| 2022-12-31 | Skr385.32 Million | -12.30% |
| 2021-12-31 | Skr439.38 Million | -53.59% |
| 2020-12-31 | Skr946.76 Million | -4.70% |
| 2019-12-31 | Skr993.49 Million | +123.49% |
| 2018-12-31 | Skr444.53 Million | -7.36% |
| 2017-12-31 | Skr479.82 Million | +762.48% |
| 2016-12-31 | Skr55.63 Million | +1163.80% |
| 2015-12-31 | Skr4.40 Million | -66.46% |
| 2014-12-31 | Skr13.12 Million | -- |